JW Pharmaceutical Future Growth

Future criteria checks 3/6

JW Pharmaceutical is forecast to grow earnings and revenue by 14.6% and 10.3% per annum respectively. EPS is expected to grow by 33.2% per annum. Return on equity is forecast to be 22.2% in 3 years.

Key information

14.6%

Earnings growth rate

33.2%

EPS growth rate

Pharmaceuticals earnings growth	35.3%
Revenue growth rate	10.3%
Future return on equity	22.2%
Analyst coverage	Low
Last updated	22 Aug 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

KOSE:A001065 - Analysts future estimates and past financials data (KRW Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	947,450	99,050	80,900	120,150	2
12/31/2025	871,750	89,550	74,300	117,750	2
12/31/2024	802,650	78,250	53,500	80,800	2
9/30/2024	736,543	69,721	65,704	95,076	N/A
6/30/2024	742,090	33,262	91,644	120,197	N/A
3/31/2024	755,737	40,621	91,518	122,485	N/A
12/31/2023	748,527	36,489	46,452	87,157	N/A
9/30/2023	736,668	25,076	42,709	76,046	N/A
6/30/2023	722,312	51,278	29,078	58,339	N/A
3/31/2023	701,393	36,949	28,177	51,238	N/A
12/31/2022	684,351	31,892	44,412	56,764	N/A
9/30/2022	660,661	12,130	32,649	46,346	N/A
6/30/2022	639,806	8,930	37,194	50,657	N/A
3/31/2022	620,832	4,584	27,866	41,446	N/A
12/31/2021	606,585	-968	5,222	18,124	N/A
9/30/2021	581,827	-1,190	4,847	19,302	N/A
6/30/2021	569,978	-3,329	22,689	36,349	N/A
3/31/2021	560,407	-8,469	28,086	43,146	N/A
12/31/2020	547,336	-15,241	48,015	63,054	N/A
9/30/2020	516,529	-31,512	65,219	77,881	N/A
6/30/2020	512,402	-33,320	36,132	49,800	N/A
3/31/2020	510,079	-23,341	43,389	56,719	N/A
12/31/2019	511,335	-25,275	42,354	55,531	N/A
9/30/2019	524,767	-9,432	3,533	16,086	N/A
6/30/2019	538,269	-8,270	40,264	51,987	N/A
3/31/2019	536,808	-659	61,987	72,856	N/A
12/31/2018	537,182	8,057	42,829	52,110	N/A
9/30/2018	534,919	9,113	56,378	66,480	N/A
6/30/2018	521,666	12,567	N/A	35,484	N/A
3/31/2018	510,284	2,417	N/A	5,770	N/A
12/31/2017	502,919	-742	N/A	33,450	N/A
9/30/2017	490,656	14,223	N/A	36,480	N/A
6/30/2017	476,290	3,697	N/A	6,678	N/A
3/31/2017	471,517	-11,472	N/A	14,991	N/A
12/31/2016	467,465	-10,934	N/A	6,739	N/A
9/30/2016	460,523	-18,836	N/A	-799	N/A
6/30/2016	452,150	-12,991	N/A	17,745	N/A
3/31/2016	447,417	2,860	N/A	28,884	N/A
12/31/2015	434,352	1,921	N/A	-4,175	N/A
9/30/2015	447,788	1,575	N/A	8,860	N/A
6/30/2015	439,802	1,064	N/A	15,286	N/A
3/31/2015	426,011	-3,378	N/A	-12,885	N/A
12/31/2014	412,791	-2,357	N/A	7,279	N/A
9/30/2014	386,064	-2,651	N/A	6,994	N/A
6/30/2014	386,067	-2,648	N/A	-16,031	N/A
3/31/2014	395,535	3,095	N/A	16,653	N/A
12/31/2013	394,182	2,275	N/A	18,725	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A001065's forecast earnings growth (14.6% per year) is above the savings rate (2.7%).

Earnings vs Market: A001065's earnings (14.6% per year) are forecast to grow slower than the KR market (29.4% per year).

High Growth Earnings: A001065's earnings are forecast to grow, but not significantly.

Revenue vs Market: A001065's revenue (10.3% per year) is forecast to grow faster than the KR market (8.8% per year).

High Growth Revenue: A001065's revenue (10.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A001065's Return on Equity is forecast to be high in 3 years time (22.2%)

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/24 18:08
End of Day Share Price	2024/12/24 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

JW Pharmaceutical Corporation is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jisoo Lee	DAOL Investment & Securities Co., Ltd.
Myung Sun Lee	DB Financial Investment Co. Ltd.
Hyung Soo Kim	Hanwha Investment & Securities Co., Ltd.